PRNewsWire
15 Jun 2026, 06:52 UTC · 3h ago
Akeso's Next-Generation HER3 ADC AK138D1 Combined with Ivonescimab: First Patient Enrolled in Phase Ib/II Breast Cancer Study, Advancing the IO2.0 + ADC2.0 Strategy
NewsImpactScreener rates every claim in this story for market impact and maps it to the tickers most exposed.






